Loss of p53 function occurs during the development of most, if not all, tumour types. This
paves the way for genomic instability, tumour-associated changes in metabolism …

The faithful maintenance of chromosome continuity in human cells during DNA replication
and repair is critical for preventing the conversion of normal diploid cells to an oncogenic …

Although restoration of p53 function is an attractive tumor-specific therapeutic strategy, it
remains unclear whether p53 loss is required only for transition through early bottlenecks in …

Mammalian cells that sustain oncogenic insults can invoke defensive programmes that
either halt their division or trigger their apoptosis, but these countermeasures must be finely …

The ARF tumour suppressor is a central component of the cellular defence against
oncogene activation. In addition to activating p53 through binding Mdm2, ARF possesses …

The DNA damage response (DDR) pathway and ARF function as barriers to cancer
development. Although commonly regarded as operating independently of each other, some …

While accumulating evidence demonstrates the existence of prostate cancer stem cells
(PCSCs), PCSCs have not been isolated and thoroughly characterized. We report here the …

The ataxia telangiectasia mutated (ATM) kinase is a key tumor suppressor that regulates
numerous cell cycle checkpoints as well as apoptosis. Here, we report that ATM is a critical …

p14ARF is a tumor suppressor that controls a well-described p53/Mdm2-dependent
checkpoint in response to oncogenic signals. Here, new insights into the tumor-suppressive …

Loss of IQGAP2 contributes to the tumorigenesis of hepatocellular carcinoma and gastric
cancer. However, whether IQGAP2 also suppresses prostate tumorigenesis remains …